ME00242B - Inhalative lösungsformulierung mit einem tiotropiumsalz - Google Patents

Inhalative lösungsformulierung mit einem tiotropiumsalz

Info

Publication number: ME00242B
Authority: ME; Montenegro
Prior art keywords: pharmaceutical preparation; preparation according; primarily; tiotropium; active substance
Prior art date: 2000-10-31

Application number

MEP-2008-407A

Other languages

English (en)

French (fr)

Unknown language (me)

Inventor

Christel Schmelzer

Petra Barth

Karin Drechsel

Humke Barbara Niklaus

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-31

Filing date

2001-10-24

Publication date

2011-05-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00242(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-10-24 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2011-02-10 Publication of MEP40708A publication Critical patent/MEP40708A/xx

2011-05-10 Publication of ME00242B publication Critical patent/ME00242B/de

Links

239000000203 mixture Substances 0.000 title claims abstract description 60
238000009472 formulation Methods 0.000 title claims abstract description 44
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 title claims description 35
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 49
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims abstract description 29
229960000257 tiotropium bromide Drugs 0.000 claims abstract description 29
239000000443 aerosol Substances 0.000 claims abstract description 20
MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 claims abstract description 11
239000013543 active substance Substances 0.000 claims description 37
239000000825 pharmaceutical preparation Substances 0.000 claims description 37
229940110309 tiotropium Drugs 0.000 claims description 22
-1 monomethyl sulfuric acid ester Chemical class 0.000 claims description 21
239000002904 solvent Substances 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
239000000126 substance Substances 0.000 claims description 19
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
229940037001 sodium edetate Drugs 0.000 claims description 13
150000003431 steroids Chemical class 0.000 claims description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 9
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 8
229960004436 budesonide Drugs 0.000 claims description 8
239000003755 preservative agent Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
230000003266 anti-allergic effect Effects 0.000 claims description 6
239000000739 antihistaminic agent Substances 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 6
229960002714 fluticasone Drugs 0.000 claims description 6
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
229960000686 benzalkonium chloride Drugs 0.000 claims description 5
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
229910052708 sodium Inorganic materials 0.000 claims description 5
239000011734 sodium Substances 0.000 claims description 5
239000007921 spray Substances 0.000 claims description 5
239000003381 stabilizer Substances 0.000 claims description 5
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
239000003963 antioxidant agent Substances 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
229950000210 beclometasone dipropionate Drugs 0.000 claims description 4
239000006184 cosolvent Substances 0.000 claims description 4
239000004615 ingredient Substances 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 3
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
229960005127 montelukast Drugs 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
229960004583 pranlukast Drugs 0.000 claims description 3
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims description 3
229960004764 zafirlukast Drugs 0.000 claims description 3
KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims description 2
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims description 2
GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims description 2
229960000428 carbinoxamine Drugs 0.000 claims description 2
OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims description 2
229960002881 clemastine Drugs 0.000 claims description 2
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 2
229960000265 cromoglicic acid Drugs 0.000 claims description 2
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 2
WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical group C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 2
229960003449 epinastine Drugs 0.000 claims description 2
229960005042 mequitazine Drugs 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
238000002663 nebulization Methods 0.000 claims description 2
RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
229960004398 nedocromil Drugs 0.000 claims description 2
238000005507 spraying Methods 0.000 claims description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
230000001387 anti-histamine Effects 0.000 claims 3
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical group [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
230000002335 preservative effect Effects 0.000 claims 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
SRJDFSRXQHFSBO-UHFFFAOYSA-N acetic acid;methylcyclopropane Chemical compound CC1CC1.CC(O)=O SRJDFSRXQHFSBO-UHFFFAOYSA-N 0.000 claims 1
230000003078 antioxidant effect Effects 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
239000013583 drug formulation Substances 0.000 claims 1
229940098779 methanesulfonic acid Drugs 0.000 claims 1
238000003825 pressing Methods 0.000 claims 1
239000003380 propellant Substances 0.000 abstract description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 20
239000000243 solution Substances 0.000 description 20
OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 11
230000007246 mechanism Effects 0.000 description 10
238000003780 insertion Methods 0.000 description 9
230000037431 insertion Effects 0.000 description 9
239000000725 suspension Substances 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
239000013078 crystal Substances 0.000 description 7
239000012530 fluid Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
238000007792 addition Methods 0.000 description 6
239000006199 nebulizer Substances 0.000 description 6
150000007513 acids Chemical class 0.000 description 5
235000015165 citric acid Nutrition 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000001816 cooling Methods 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
229960005070 ascorbic acid Drugs 0.000 description 4
239000007789 gas Substances 0.000 description 4
239000012669 liquid formulation Substances 0.000 description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
229940125715 antihistaminic agent Drugs 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
239000002585 base Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229950004959 sorbitan oleate Drugs 0.000 description 3
238000005406 washing Methods 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000000043 antiallergic agent Substances 0.000 description 2
239000013011 aqueous formulation Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
238000009835 boiling Methods 0.000 description 1
150000003842 bromide salts Chemical class 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
RMCDUNHIVVEEDD-UHFFFAOYSA-N methylcyclopropane Chemical compound [CH2]C1CC1 RMCDUNHIVVEEDD-UHFFFAOYSA-N 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000004448 titration Methods 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Dispersion Chemistry (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MEP-2008-407A 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz ME00242B (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10054042		2000-10-31
PCT/EP2001/012296 WO2002036591A2 (de)	2000-10-31	2001-10-24	Inhalative lösungsformulierung mit einem tiotropiumsalz
YU33103A YU33103A (sh)	2000-10-31	2001-10-24	Formulacija rastvora za inhalaciju sa soli tiotropijuma

Publications (2)

Publication Number	Publication Date
MEP40708A MEP40708A (en)	2011-02-10
ME00242B true ME00242B (de)	2011-05-10

Family

ID=7661727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2008-407A ME00242B (de)	2000-10-31	2001-10-24	Inhalative lösungsformulierung mit einem tiotropiumsalz

Country Status (32)

Country	Link
EP (1)	EP1335729A2 (de)
JP (1)	JP4559703B2 (de)
KR (1)	KR100983208B1 (de)
CN (1)	CN1237970C (de)
AR (1)	AR038765A1 (de)
AU (2)	AU2002221741B2 (de)
BG (1)	BG66425B1 (de)
BR (1)	BR0115016A (de)
CA (1)	CA2427583C (de)
CZ (1)	CZ305033B6 (de)
DE (1)	DE10152369A1 (de)
EA (1)	EA009068B1 (de)
EC (1)	ECSP034570A (de)
EE (1)	EE05343B1 (de)
HR (1)	HRP20030337A2 (de)
HU (1)	HUP0301377A3 (de)
IL (2)	IL155676A0 (de)
ME (1)	ME00242B (de)
MX (1)	MXPA03003750A (de)
MY (1)	MY132777A (de)
NO (1)	NO332524B1 (de)
NZ (1)	NZ526024A (de)
PE (1)	PE20020518A1 (de)
PL (1)	PL361001A1 (de)
SA (1)	SA01220503B1 (de)
SK (1)	SK288031B6 (de)
TW (1)	TWI296934B (de)
UA (1)	UA76435C2 (de)
UY (1)	UY26991A1 (de)
WO (1)	WO2002036591A2 (de)
YU (1)	YU33103A (de)
ZA (1)	ZA200303045B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001083800A2 (en)	2000-04-28	2001-11-08	Kosan Biosciences, Inc.	Heterologous production of polyketides
US20030235538A1 (en)	2002-04-09	2003-12-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Method for the administration of an anticholinergic by inhalation
GB2389530B (en)	2002-06-14	2007-01-10	Cipla Ltd	Pharmaceutical compositions
CA2544611A1 (en) *	2003-10-09	2005-04-21	Inverseon, Inc.	Method of treating airway diseases with beta-adrenergic inverse agonists
SE0303269L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Medicinsk produkt
SI1863476T1 (sl) *	2005-03-16	2016-05-31	Meda Pharma Gmbh & Co. Kg	Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
AU2007267523B2 (en) *	2006-05-26	2012-02-09	Dey, L.P.	Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
CN100446770C (zh) *	2007-01-10	2008-12-31	上海现代药物制剂工程研究中心有限公司	丙酸培氯米松水雾剂
TR200907237A2 (tr) *	2009-09-23	2011-04-21	B�Lg�� Mahmut	Tiotropyum kuru toz kombinasyonu
CN111936124A (zh) *	2018-07-26	2020-11-13	四川海思科制药有限公司	一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用
CN116196298A (zh) *	2018-07-26	2023-06-02	四川海思科制药有限公司	一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0504112A3 (en) *	1991-03-14	1993-04-21	Ciba-Geigy Ag	Pharmaceutical aerosol formulations
DE4203306A1 (de) *	1992-02-06	1993-08-12	Ig Spruehtechnik Gmbh	Asthma oder pulmonal-aerosolzubereitungen mit lecithin
BR9609307B1 (pt) *	1995-06-27	2010-03-09		preparação farmacêutica para produção de aerossóis inaláveis isentos de propelentes para administração nos pulmões, bem como aerossol compreendendo a mesma.
US5824669A (en) *	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
CA2256721A1 (en) *	1996-06-04	1997-12-11	The Procter & Gamble Company	A nasal spray containing an intranasal steroid and an antihistamine
DE19653969A1 (de) *	1996-12-20	1998-06-25	Boehringer Ingelheim Kg	Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
JPH10298107A (ja) *	1997-04-25	1998-11-10	Taisho Pharmaceut Co Ltd	医薬組成物
ATE234604T1 (de) *	1998-08-04	2003-04-15	Jago Res Ag	Medizinische aerosolformulierungen
DE19847968A1 (de) *	1998-10-17	2000-04-20	Boehringer Ingelheim Pharma	Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen

2001
- 2001-10-24 YU YU33103A patent/YU33103A/sh unknown
- 2001-10-24 HU HU0301377A patent/HUP0301377A3/hu unknown
- 2001-10-24 AU AU2002221741A patent/AU2002221741B2/en not_active Expired
- 2001-10-24 EP EP01992710A patent/EP1335729A2/de not_active Ceased
- 2001-10-24 CN CNB018183271A patent/CN1237970C/zh not_active Expired - Lifetime
- 2001-10-24 IL IL15567601A patent/IL155676A0/xx unknown
- 2001-10-24 ME MEP-2008-407A patent/ME00242B/de unknown
- 2001-10-24 HR HR20030337A patent/HRP20030337A2/hr not_active Application Discontinuation
- 2001-10-24 DE DE10152369A patent/DE10152369A1/de not_active Withdrawn
- 2001-10-24 CZ CZ2003-1487A patent/CZ305033B6/cs not_active IP Right Cessation
- 2001-10-24 SK SK526-2003A patent/SK288031B6/sk not_active IP Right Cessation
- 2001-10-24 JP JP2002539350A patent/JP4559703B2/ja not_active Expired - Lifetime
- 2001-10-24 EE EEP200300202A patent/EE05343B1/xx unknown
- 2001-10-24 BR BR0115016-2A patent/BR0115016A/pt active Search and Examination
- 2001-10-24 EA EA200300483A patent/EA009068B1/ru not_active IP Right Cessation
- 2001-10-24 AU AU2174102A patent/AU2174102A/xx active Pending
- 2001-10-24 PL PL01361001A patent/PL361001A1/xx not_active Application Discontinuation
- 2001-10-24 WO PCT/EP2001/012296 patent/WO2002036591A2/de not_active Ceased
- 2001-10-24 KR KR1020037006001A patent/KR100983208B1/ko not_active Expired - Lifetime
- 2001-10-24 NZ NZ526024A patent/NZ526024A/en not_active IP Right Cessation
- 2001-10-24 CA CA002427583A patent/CA2427583C/en not_active Expired - Fee Related
- 2001-10-24 UA UA2003054960A patent/UA76435C2/uk unknown
- 2001-10-24 MX MXPA03003750A patent/MXPA03003750A/es active IP Right Grant
- 2001-10-29 UY UY26991A patent/UY26991A1/es not_active Application Discontinuation
- 2001-10-29 TW TW090126752A patent/TWI296934B/zh not_active IP Right Cessation
- 2001-10-29 MY MYPI20014987A patent/MY132777A/en unknown
- 2001-10-29 PE PE2001001072A patent/PE20020518A1/es active IP Right Grant
- 2001-10-31 AR ARP010105088A patent/AR038765A1/es not_active Application Discontinuation
- 2001-11-03 SA SA01220503A patent/SA01220503B1/ar unknown
2003
- 2003-04-16 BG BG107726A patent/BG66425B1/bg unknown
- 2003-04-17 ZA ZA200303045A patent/ZA200303045B/xx unknown
- 2003-04-28 EC EC2003004570A patent/ECSP034570A/es unknown
- 2003-04-29 NO NO20031914A patent/NO332524B1/no not_active IP Right Cessation
- 2003-04-30 IL IL155676A patent/IL155676A/en active IP Right Grant

Also Published As

Publication number	Publication date
AU2174102A (en)	2002-05-15
CN1237970C (zh)	2006-01-25
NO20031914D0 (no)	2003-04-29
UY26991A1 (es)	2002-06-20
EA009068B1 (ru)	2007-10-26
SK288031B6 (sk)	2012-12-03
YU33103A (sh)	2006-05-25
JP4559703B2 (ja)	2010-10-13
EE200300202A (et)	2003-10-15
MY132777A (en)	2007-10-31
CA2427583A1 (en)	2002-05-10
IL155676A0 (en)	2003-11-23
EA200300483A1 (ru)	2003-12-25
AR038765A1 (es)	2005-01-26
JP2004523482A (ja)	2004-08-05
WO2002036591A2 (de)	2002-05-10
CZ20031487A3 (cs)	2003-09-17
HRP20030337A2 (en)	2005-04-30
SK5262003A3 (en)	2003-10-07
ZA200303045B (en)	2004-04-22
PE20020518A1 (es)	2002-07-12
HUP0301377A2 (hu)	2003-10-28
MEP40708A (en)	2011-02-10
BR0115016A (pt)	2005-05-03
AU2002221741B2 (en)	2007-04-05
NO20031914L (no)	2003-06-23
TWI296934B (en)	2008-05-21
BG66425B1 (bg)	2014-04-30
KR20040010552A (ko)	2004-01-31
IL155676A (en)	2012-05-31
EP1335729A2 (de)	2003-08-20
ECSP034570A (es)	2003-06-25
DE10152369A1 (de)	2002-05-08
MXPA03003750A (es)	2004-10-15
WO2002036591A3 (de)	2002-07-25
NO332524B1 (no)	2012-10-08
NZ526024A (en)	2005-10-28
CZ305033B6 (cs)	2015-04-08
SA01220503B1 (ar)	2007-03-10
BG107726A (bg)	2004-11-30
CA2427583C (en)	2008-02-12
KR100983208B1 (ko)	2010-09-20
CN1473044A (zh)	2004-02-04
PL361001A1 (en)	2004-09-20
EE05343B1 (et)	2010-10-15
HK1060569A1 (en)	2004-08-13
UA76435C2 (en)	2006-08-15
HUP0301377A3 (en)	2005-12-28

Publication	Publication Date	Title
US6890517B2 (en)	2005-05-10	Inhalable formulation of a solution containing a tiotropium salt
CA2440699C (en)	2010-06-01	Compounds for treating inflammatory diseases
US20020111363A1 (en)	2002-08-15	Inhalable formulation of a solution containing a tiotropium salt
US20020183292A1 (en)	2002-12-05	Pharmaceutical compositions based on anticholinergics and corticosteroids
JP2004515528A (ja)	2004-05-27	抗コリン作用薬及びシクレソニドをベースとする新規薬剤組成物
RS50286B (sr)	2009-09-08	Nove kompozicije lekova bazirane na solima tiotropijuma i solima salmeterola
JP4559703B2 (ja)	2010-10-13	チオトロピウム塩を含有する溶液の吸入組成物
RS89904A (sr)	2006-10-27	Medikamenti koji sadrže steroide i novi lek antiholinesteraze
RS87904A (sr)	2006-12-15	Aerosolna formulacija za inhaliranje koja sadrži triotropijumovu so
ME00244B (de)	2011-05-10	Inhalative lösungsformulierung mit einem tiotropiumsalz
HK1060524B (en)	2008-09-05	Inhalative solution formulation containing a tiotropium salt
HK1123745A (en)	2009-06-26	Inhalation formulation of the solution comprising tiotropium salt